Clinical trials: IgAN - IgA Nephropathy
IgA Glomerulonephritis
Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy
OBJECTIVES: Evaluate the efficacy of alternate day prednisone versus daily fish oil supplements in slowing or preventing the decline in renal function in children, adolescents, and young adults with moderate to severe…
- Trial name
- NCT00004448
- Testing
- omega-3 fatty acids, prednisone
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Progressive IgA Nephropathy, Proteinuria
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in…
- Trial name
- NCT02282930
- Testing
- ACTH (Acthar) Gel
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
IgA Nephropathy
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)
This Phase 3, open-label study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of sibeprenlimab administered subcutaneously every 4 weeks in pediatric…
- Trial name
- NCT07770815
- Testing
- Sibeprenlimab, Standard of care
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
IGA Nephropathy
Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy
This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of reh-acteoside therapy for patients of IgA nephropathy.
- Trial name
- NCT02662283
- Testing
- Prednisolone, Reh-acteoside
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
IgA Nephropathy
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
-IgA nephropathy is the most common primary glomerular disease in China, Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease.
- Trial name
- NCT02231125
- Testing
- Losartan, Abelmoschus manihot
- Where
- 88 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Chen Xiangmei
Glomerulonephritis
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104 in participants with IgAN and C3G. The study will start with enrolling the IgAN cohort.
- Trial name
- NCT05517980
- Testing
- KP104
- Volunteers
- 52 people
- Sponsor
- Kira Pharmacenticals (US), LLC.
IgA Nephropathy
Effect of Finerenone in IgA Nephropathy
The aim of this trial is to conduct a randomized, multicenter, placebo-controlled, double-blind clinical trial to determine the safety and efficacy of Finerenone in reducing proteinuria and protecting renal function in patients…
- Trial name
- FIGHT (NCT06580288)
- Testing
- Finerenone
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
IgA Nephropathy
Study of Telitacicept in Patients With Refractory IgA Nephropathy
The goal of this clinical trial is to explore the effectiveness and safety of Telitacicept in adults with refractory IgA nephropathy.
- Trial name
- NCT05596708
- Testing
- Telitacicept
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
IgA Nephropathy
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.
- Trial name
- NCT00793585
- Testing
- allopurinol, continue their usual therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Glomerulonephritis, IGA, Probiotics
Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy
The goal of this clinical trial is to evaluate the efficacy and safety of probiotics combined with enteric-coated budesonide capsule in patients with IgA nephropathy on the basis of optimized RAS blockade therapy, and to explore…
- Conditions
- Glomerulonephritis, IGA, Probiotics, Budesonide
- Trial name
- NCT06528015
- Testing
- probiotics combined with enteric-coated budesonide capsule
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Gang Xu
IgA Nephropathy, Renal Insufficiency, Chronic
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Global Burden of Diseases ranks chronic kidney disease (CKD) as the 12th leading cause of death, with an estimated 20% increase from 2010 to 2019.
- Conditions
- IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
- Trial name
- IA-GRACE-IgANT (NCT06676384)
- Testing
- Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC
- Where
- 12 sites in India
- Volunteers
- 585 people
- Sponsor
- Christian Medical College, Vellore, India
Glomerulonephritis, IGA Nephropathy
A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
a statement of the study hypothesis:the effect of valsartan in patients with IgA nephropathy have been proved,and the efficacy of probucol in combination with valsartan is to be proved in patients with IgA nephropathy.
- Trial name
- NCT00426348
- Testing
- Valsartan, Probucol
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Guangdong Provincial People's Hospital
IgA Nephropathy
The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients
The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on time to doubling of serum creatinine or the onset of end stage renal disease in patients with advanced IgA nephropathy who are treated…
- Trial name
- MAIN (NCT01854814)
- Testing
- Mycophenolate mofetil, Losartan
- Where
- 3 sites in China
- Volunteers
- 238 people
- Sponsor
- Fan Fan Hou
Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States [US], United…
- Trial name
- HONUS (NCT05200871)
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 487 people
- Sponsor
- Travere Therapeutics, Inc.
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
IgA Nephropathy, Glomerular Diseases
Biomarkers for the Progression of IgA Nephropathy
IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and an important cause of end stage renal disease.
- Trial name
- NCT02529722
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Istanbul University
IgA Nephropathy
Treatment of IgA Nephropathy According to Renal Lesions
TIGER study (Treatment of IgA nEphropathy according to Renal lesions) is a prospective openly randomized controlled study. The main objective is to evaluate the efficacy of early corticotherapy + Renin Angiotensin System (RAS)…
- Trial name
- TIGER (NCT03188887)
- Testing
- corticotherapy, Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immunoglobulin A Nephropathy
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy
- Trial name
- NCT05248646
- Testing
- Sibeprenlimab 400 mg
- Where
- 308 sites in United States, Argentina and 29 more
- Volunteers
- 530 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
IgA Nephropathy
IgA Nephropathy, Lymphocyte Homing and IgA Class Switch
IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure.
- Trial name
- NIDOCIGA (NCT01775527)
- Testing
- blood test
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Glomerulonephritis, Immunoglobulin A (IgA)
Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1
Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. IgAN is progressive, particularly when patients have a significant proteinuria (proteinuria >1g/g creatinine), impaired kidney function, or…
- Trial name
- BEST-IgAN-1 (NCT03357653)
- Testing
- Losartan group
- Volunteers
- 174 people
- Sponsor
- Ewha Womans University